Business Combination, Contingent Consideration Arrangements, Earned

No definition available.

Name:	ibrx_BusinessCombinationContingentConsiderationArrangementsEarned
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Business Combination, Contingent Consideration Arrangements, Settlements

+ References

No definition available.

+ Details

Name:	ibrx_BusinessCombinationContingentConsiderationArrangementsSettlements
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent value rights obligations.

+ References

No definition available.

+ Details

Name:	ibrx_ContingentValueRightsObligations
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Minimum net sales milestone contingent value rights obligation.

+ References

No definition available.

+ Details

Name:	ibrx_MinimumNetSalesMilestoneContingentValueRightsObligation
Namespace Prefix:	ibrx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of wholly-owned subsidiary.

+ References

No definition available.

+ Details

Name:	ibrx_PercentageOfWhollyOwnedSubsidiary
Namespace Prefix:	ibrx_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 8
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479637/805-30-30-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 30
-Paragraph 7
-SubTopic 30
-Topic 805
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479637/805-30-30-7

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-4

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsObligationSalesMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_DrSoonShiongAndRelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_AltorStockholdersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=ibrx_VivaBioCellMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Contingent Consideration Related to Business Combinations - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Apr. 30, 2015	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2017
Altor BioScience, LLC \| Contingent Value Rights Obligation, Sales Milestone
Business Acquisition [Line Items]
Contingent value rights obligations					$ 304.0
Minimum net sales milestone contingent value rights obligation					$ 1,000.0
Altor BioScience, LLC \| Dr Soon Shiong And Related Party \| Contingent Value Rights Obligation, Sales Milestone
Business Acquisition [Line Items]
Contingent value rights obligations		$ 139.8
Altor BioScience, LLC \| Altor Stockholders \| Contingent Value Rights Obligation, Sales Milestone
Business Acquisition [Line Items]
Contingent value rights obligations		164.2
VivaBioCell
Business Acquisition [Line Items]
Ownership percentage acquired	100.00%
Business combination, consideration transferred	$ 0.7
Contingent consideration arrangements, earned				$ 0.8
Contingent consideration arrangements, paid			$ 0.3	$ 0.4
Maximum milestone payment due if certain conditions are met		$ 2.2